InspireMD Achieves Record Q3 Revenue with CGuard Success

InspireMD ( (NSPR) ) just unveiled an update.

InspireMD, Inc. has reported record revenue for Q3 2024, driven by its CGuard Prime carotid stent system, which is moving towards potential U.S. approval. Recent developments include submitting a PMA application to the FDA and receiving IDE approval for pivotal trials. The company anticipates a U.S. commercial launch in early 2025, supported by a new Miami headquarters. Despite increased operating expenses, InspireMD’s strategic advancements position it for growth in the carotid artery disease treatment market.

See more insights into NSPR stock on TipRanks’ Stock Analysis page.